Position in EXEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$371,212
-$114,205 QoQ
Shares Held
8,655
-21.9% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026AlphaCore Capital LLC holds $8,201,769 across 16 Biotechnology names. EXEL ranks #5 (4.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
41,765 | $2,699,271 | |
| 2 | IDYA |
IDEAYA Biosciences, Inc.
|
57,406 | $1,912,767 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,626 | $1,172,614 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
856 | $661,379 | |
| 5 | EXEL |
Exelixis, Inc.
This page
|
8,655 | $371,212 | |
| 6 | TECH |
BIO-TECHNE Corp
|
5,076 | $265,271 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
4,173 | $235,732 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
2,762 | $207,398 |
All Filings in EXEL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $371,212 | 8,655 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $485,417 | 11,075 | Shares | Sole | 2026-02-05 | |
| No filing history on record for this holder in this stock. | ||||||